Disclosed is a novel amine compound represented by the general formula (I) below, a pharmaceutically acceptable acid addition salt of the compound, or a hydrate or solvate of the compound or the salt, which is excellent in an immunosuppressing effect, a rejection response-suppressing effect and the like and is reduced in adverse side effects such as bradycardia. Also disclosed is a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. (I) wherein R represents a hydrogen atom or P(=O)(OH)； X represents an oxygen or sulfur atom； Y represents CHCH or CH=CH； R represents an alkyl having 1-4 carbon atoms which is substituted by a halogen atom or a cyano； R represents an alky having 1-4 carbon atoms which may be substituted by a hydroxyl group or a halogen atom； R and R independently represent a hydrogen atom or an alkyl having 1-4 carbon atoms； and n represents 5-8.
